Amit Kumar - 30 Oct 2025 Form 4 Insider Report for Anixa Biosciences Inc (ANIX)

Reporting relationship: Chief Executive Officer
Issuer ticker: ANIX
Reported as of: 30 Oct 2025
Net transaction value: -$103,922
SEC form: 4
Accepted by SEC: 31 Oct 2025, 09:13:33 UTC
Prior SEC filing: 31 Jul 2025
Next SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Amit Kumar

Key filing fact

Amit Kumar filed Form 4 for Anixa Biosciences Inc (ANIX) on 31 Oct 2025.

Key facts

This page summarizes Amit Kumar's Form 4 filing for Anixa Biosciences Inc (ANIX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 31 Oct 2025, 09:13.

Change

Previous filing in this sequence was filed on 31 Jul 2025.
Current net transaction value: -$103,922.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001191905 Primary reporting owner

KUMAR AMIT

Relationship: Chief Executive Officer
Address: C/O ANIXA BIOSCIENCES, INC., 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE,
Signature: /s/ Amit Kumar
Signature date: 31 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANIX transaction

Common Stock

Options Exercise

Transaction value: $584,000
Shares: +200,000
Change %: +34%
Price: $2.92
Shares after: 779,925
Date: 30 Oct 2025
Ownership: Direct

ANIX transaction

Common Stock

Tax liability

Transaction value: $687,922
Shares: -169,439
Change %: -22%
Price: $4.06
Shares after: 610,486
Date: 30 Oct 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ANIX transaction Derivative

Employee Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -200,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 30 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 200,000
Exercise price: $2.92
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The reporting person exercised the stock options at this time due to their upcoming expiration on February 18, 2026. The disposal of shares reported herein represents shares withheld by Anixa Biosciences, Inc. (the "registrant") to (i) cover the exercise price of the stock options and (ii) satisfy tax withholding obligations in connection with the exercise of the stock options. Dr. Kumar did not sell any shares in connection with the exercise of the options.

Footnote F2

Right-To-Buy, pursuant to a stock option grant dated February 18, 2016.

Footnote F3

The option vested in 36 consecutive monthly installments beginning on March 31, 2016.